The crucial role of GS-CHO innovation in biopharmaceutical progress
Learn how GS-CHO systems are advancing to improve yields and quality in biomanufacturing, meeting the rising need for effective therapeutic proteins.
Cancer
- Latest Posts
News and Trends 27 Aug 2024
Could microbiome drugs be the key to unlocking checkpoint inhibitors’ potential?
As Microbiotica announces phase 1 approval for two microbiome drugs we delve into their potential in oncology and beyond.
News and Trends 14 Aug 2024
CAR-T drugs and parkinsonism: a cause for concern?
CAR-T therapies come with boxed warnings of serious neurotoxic side effects. Now, growing concerns over parkinsonism have led to a clinical trial halt.
News and Trends 13 Aug 2024
Biologics vs. drugs: What does Ipsen’s lost case against the FDA mean for the industry?
Ipsen has lost a court case against U.S. regulators to have its blockbuster cancer medication Somatuline Depot regarded as a biologic instead of a drug.
More News! 23 Jul 2024
First AKT-targeting drug capivasertib to hit the market, could it open the door for more?
As AstraZeneca and Astex’s capivasertib gains market presence in breast cancer, could it be the time for AKT inhibitors? Let’s find out!
News and Trends 16 Jul 2024
German biotech raises $150M on its way to tackle cancer therapy resistance
On its way to tackle cancer therapy resistance with its monoclonal antibody visugromab, CataLym completes a $150 million series D round.
ADVERTISEMENT
ADVERTISEMENT
Podcast 5 Jul 2024
The radiotherapeutics boom
The field of radiotherapeutics is a hot topic currently. Listen to our conversation with three experts in the field.
Inside Labiotech 3 Jul 2024
2024 survey: What can Labiotech readers tell us about the biotech industry?
Explore key insights into the latest biotech industry trends based on our 2024 reader survey findings. Discover more now!
In Depth 28 Jun 2024
Going nuclear: radiopharmaceuticals funding sees surge in 2024
Emerging as a new class of drugs, radiopharmaceuticals are all the rage in cancer treatment research as biotechs nab major funding deals.
In Depth 27 Jun 2024
The 2024 drug approval list: Eight new treatments you should know about
In this article, we take a look at eight much-anticipated drugs that have been approved by regulators so far this year.
Podcast 21 Jun 2024
How ADCs can deliver death cap mushroom toxins to treat cancer
Listen to our conversation with Heidelberg Pharma about its lead amanitin-based ADC product candidate, HDP-101.
Best in Biotech 13 Jun 2024
Eight companies tackling cancer with allogeneic cell therapy in 2024
Unlike autologous cell therapy, where the patient’s own cells are used, allogeneic cell therapy companies leverage donor cells, which can come from various sources such as bone marrow or umbilical cord blood. In allogeneic cell therapy, healthy donor cells are harvested, processed, and then infused into the patient. These donor cells can differentiate into various […]
ADVERTISEMENT
